2021-2032 All Rights Reserved. Online Journal of Bioinformatics. You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to onlinejournals@gmail.com publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. Linking: To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.


OJBTM

Online Journal of Bioinformatics

Established 1995

ISSN  1443-2250

 

Volume 23 (3):287-297, 2022.


In silico binding dipeptidyl peptidase target protein for diabetes mellitus 2.

 

Rajeev Sharmah, Subrata Sinha, Surabhi Johari

 

Center for Bioinformatics Studies, Department of Life sciences, Dibrugarh University, Dibrugarh Assam, India.

 

ABSTRACT

 

Sharmah R, Sinha S, Johari S., In silico binding dipeptidyl peptidase target protein for diabetes mellitus 2, Onl J Bioinform., 23 (3):287-297, 2022. Diabetes mellitus type 2 is caused by lack of insulin production. Di-peptidyl peptidase IV (DPP IV) protease degrades incretins that stimulate secretion of insulin so its inhibition should boost insulin. We retrieved sequence DPP IV for In silico docking. We designed drug using methylamine as lead molecule. Results from OSIRIS and MOLINSPIRATION show the methyl amines with drug score of 0.83. The drug (3-[3-(methyl amino) cyclopentyl] pentane-1, 2-diol) was non-mutagenic, irritant, tumerogenic or reproductive effects with low molecular weight drug.

 

Key-words: Diabetes, Glucagon like peptide, Dipeptidyl Peptidase IV, Drug.


MAIN

 

FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE)